Pirtobrutinib,Venetoclax,Rituximab
Eli Lilly,Roche,Abbvie
['leusm', 'cll', 'lymsm', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)', 'loxo']
at #eha2023 - learn about the genomic evolution &amp; resistance to a highly selective, non-covalent (reversible) btk inhibitor in patients with cll that were previously treated with a covalent btk inhibitor (cbtki). #leusm #lymsm see the details here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK